Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:38:02.277Z.
Calculation as of: 2026-10-06T16:38:02.277Z.
Quote observation: 2026-10-06T16:34:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a8aae8e93f82a899e51ff603ce0499f2ee8a4244ac8b174beef8711f00adb15
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spectral AI, Inc. (MDAI) | $53.76M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.63M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $53.22M | N/A | 2.27 | 2.27 | 2.27 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.28M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | N/A | 135.17 | 135.17 | 135.17 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.72M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 10.03 | 4.82 | 27.98 | 18.54 |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.08M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.69
Forward EPS (Est.)
$-0.47
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
